A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Recruiting now · Phase 3
Conditions studied: Refractory or Relapsed Multiple Myeloma
In brief
This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma
Key facts
- Study ID
- NCT06952478
- Run by
- Celltrion
- People needed
- 486
- Starts
- 2025-08-12
- Expected to finish
- 2029-06-25
- Last updated by the study team
- 2025-08-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Taipei Veterans General Hospital — Taipei, Beitou District, Taiwan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.